Switching Female Schizophrenic Patients to Quetiapine from Conventional Antipsychotic Drugs: Effects on Hyperprolactinemia

Introduction: Conventional antipsychotic medications are associated with elevated prolactin levels, resulting in hyperprolactinemia and a number of unwanted side effects. Several atypical antipsychotics, on the other hand, are less likely to evoke hyperprolactinemia. The aim of this study was to investigate the prevalence of hyperprolactinemia induced by conventional antipsychotic drugs, examine changes in serum prolactin levels and psychiatric symptoms after switching to quetiapine, and identify the relevant characteristics of patients who may be suitable to switch to quetiapine. Method: Sixty-nine of 74 consecutive female patients who had received conventional antipsychotic drugs were initially included in the study. Of these, 49 (71 %) patients suffered from hyperprolactinemia, of which a further 25 were subsequently switched to quetiapine. Psychiatric symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS), and serum prolactin levels were measured just before and at 4 and 8 weeks after switching. Results: Eight of the 25 (32 %) ”switch” patients dropped out due to psychotic exacerbation during the 8 weeks. In the remaining 17 (68 %) patients, serum prolactin levels were significantly decreased without any significant change in PANSS scores after switching. The 17 patients who completed the switch had previously demonstrated significantly lower positive symptom scores compared to the 8 dropout patients. Conclusion: The present findings suggest that 71 % of female patients receiving conventional antipsychotic drugs may suffer from hyperprolactinemia and that approximately two-thirds of patients can be switched to quetiapine, resulting in an improvement in hyperprolactinemia. The main characteristic of the switched patients may be fewer positive symptoms.

References

• 1 American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatr 1997 154: 1-63
• 2 Halbreich U, Kinon B J, Gilmore J A, Kahn L S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects.  Psychoneuroendocrinology. 2003;  28 (suppl 1) 3-67
• 3 Hamner M B, Arvanitis L A, Miller B G, Link C GG, Hong W W. Plasma prolactin in schizophrenia subjects treated with Seroquel^TM (ICI204,636).  Psychopharmacol Bull. 1996;  32 107-110
• 4 Keller R, Mongini F. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.  Neurol Sci. 2002;  23 233-235
• 5 Kinon B J, Gilmore J A, Liu H, Halbreich U M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.  Psychoneuroendocrinology. 2003;  28 (suppl 2) 55-68
• 6 Kropp S, Ziegenbein M, Grohmann R, Engel R R, Degner D. Galactorrhea due to psychotropic drugs.  Pharmacopsychiatry. 2004;  37 (suppl 1) 84-88
• 7 Kunwar A R, Megna J L. Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine.  Ann Pharmacother. 2003;  37 206-208
• 8 Notelovitz M, Ware M D, Buhi W C, Dougherty M C. Prolactin: effects of age, menopausal status, and exogenous hormones.  Am J Obstet Gynecol. 1982;  143 225-227
• 9 Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D₂ receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.  Am J Psychiatr. 1999;  156 876-884
• 10 Wieck A, Haddad P M. Antipsychotic-induced hyperprolactinemia in women: pathphysiology, severity and consequences: selective literature review.  Br J Psychiatr. 2003;  182 199-204